Metropolitan Life Insurance Company (MetLife)’s NeoGenomics NEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-6,980
| Closed | -$110K | – | 1364 |
|
|
2024
Q1 | $110K | Sell |
6,980
-617
| -8% | -$9.53K | ﹤0.01% | 1000 |
|
|
2023
Q4 | $123K | Hold |
7,597
| – | – | 0.01% | 965 |
|
|
2023
Q3 | $93.4K | Buy |
7,597
+720
| +10% | +$10.7K | ﹤0.01% | 1057 |
|
|
2023
Q2 | $111K | Hold |
6,877
| – | – | 0.01% | 970 |
|
|
2023
Q1 | $120K | Sell |
6,877
-701
| -9% | -$9.99K | 0.01% | 914 |
|
|
2022
Q4 | $70K | Hold |
7,578
| – | – | ﹤0.01% | 1267 |
|
|
2022
Q3 | $65.2K | Buy |
7,578
+611
| +9% | +$6.07K | ﹤0.01% | 1282 |
|
|
2022
Q2 | $56.8K | Hold |
6,967
| – | – | ﹤0.01% | 1424 |
|
|
2022
Q1 | $84.6K | Sell |
6,967
-23,030
| -77% | -$485K | ﹤0.01% | 1305 |
|
|
2021
Q4 | $1.02M | Hold |
29,997
| – | – | 0.01% | 944 |
|
|
2021
Q3 | $1.45M | Sell |
29,997
-746
| -2% | -$34.5K | 0.02% | 707 |
|
|
2021
Q2 | $1.39M | Buy |
30,743
+1,964
| +7% | +$87K | 0.02% | 765 |
|
|
2021
Q1 | $1.39M | Sell |
28,779
-1,128
| -4% | -$58.7K | 0.02% | 741 |
|
|
2020
Q4 | $1.61M | Hold |
29,907
| – | – | 0.02% | 585 |
|
|
2020
Q3 | $1.1M | Sell |
29,907
-1,702
| -5% | -$63.3K | 0.02% | 685 |
|
|
2020
Q2 | $979K | Buy |
31,609
+2,999
| +10% | +$83.1K | 0.02% | 754 |
|
|
2020
Q1 | $790K | Sell |
28,610
-1,330
| -4% | -$39.8K | 0.02% | 803 |
|
|
2019
Q4 | $876K | Sell |
29,940
-673
| -2% | -$16K | 0.01% | 970 |
|
|
2019
Q3 | $585K | Buy |
30,613
+3,631
| +13% | +$85.2K | 0.01% | 1193 |
|
|
2019
Q2 | $592K | Buy |
26,982
+487
| +2% | +$10.7K | 0.01% | 1197 |
|
|
2019
Q1 | $542K | Buy |
26,495
+6,481
| +32% | +$113K | 0.01% | 1244 |
|
|
2018
Q4 | $252K | Hold |
20,014
| – | – | 0.01% | 1650 |
|
|
2018
Q3 | $307K | Buy |
20,014
+873
| +5% | +$12.1K | 0.01% | 1702 |
|
|
2018
Q2 | $251K | Hold |
19,141
| – | – | ﹤0.01% | 1790 |
|
|
2018
Q1 | $156K | Hold |
19,141
| – | – | ﹤0.01% | 2048 |
|
|
2017
Q4 | $170K | Sell |
19,141
-18,291
| -49% | -$169K | ﹤0.01% | 2003 |
|
|
2017
Q3 | $417K | Sell |
37,432
-1,409
| -4% | -$13.7K | ﹤0.01% | 1809 |
|
|
2017
Q2 | $348K | Hold |
38,841
| – | – | ﹤0.01% | 1963 |
|
|
2017
Q1 | $306K | Sell |
38,841
-853
| -2% | -$6.95K | ﹤0.01% | 1985 |
|
|
2016
Q4 | $340K | Hold |
39,694
| – | – | ﹤0.01% | 2009 |
|
|
2016
Q3 | $326K | Buy |
39,694
+180
| +0.5% | +$1.51K | ﹤0.01% | 2002 |
|
|
2016
Q2 | $318K | Hold |
39,514
| – | – | ﹤0.01% | 1991 |
|
|
2016
Q1 | $266K | Hold |
39,514
| – | – | ﹤0.01% | 1988 |
|
|
2015
Q4 | $311K | Hold |
39,514
| – | – | ﹤0.01% | 1933 |
|
|
2015
Q3 | $226K | Sell |
39,514
-1,172
| -3% | -$7.26K | ﹤0.01% | 2203 |
|
|
2015
Q2 | $220K | Buy |
+40,686
| New | +$210K | ﹤0.01% | 2337 |
|
Other funds holding NEO
GF
FLAM
Metropolitan Life Insurance Company (MetLife)'s NEO Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of NeoGenomics (NEO) in Q2 2024, closing a stake of 6,980 shares — an estimated $110K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in NEO in Q2 2015 and held it in 36 quarters. The position peaked at $1.61M in Q4 2020. 259 funds tracked by Wall St. Rank hold NEO as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining NeoGenomics position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 6,980 NeoGenomics shares in Q2 2024, an estimated $110K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in NeoGenomics in Q2 2015 and held it in 36 quarters.
- Metropolitan Life Insurance Company (MetLife)'s NeoGenomics position peaked at $1.61M in Q4 2020.
- 259 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.